Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HENRIK BO ILLUM

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1982805164
CMS profile
818448
Location
BEDFORD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$11.92

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $11.92 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Gilead Sciences, Inc. $11.92 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HENRIK BO ILLUM

NPI 1982805164 · CMS profile ID 818448

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BEDFORD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1982805164?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HENRIK BO ILLUM, NPI 1982805164, CMS profile ID 818448. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1982805164?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). HENRIK BO ILLUM, NPI 1982805164, CMS profile ID 818448. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1982805164?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
HENRIK BO ILLUM, NPI 1982805164, CMS profile ID 818448, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1982805164?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $11.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845874393 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $218.19 5
PY2021 $11.92 1
PY2022 $388.68 8
PY2023 $308.84 15
PY2024 $466.63 22
PY2025 $915.63 26

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $30,785.70 23
PY2024 Principal investigator $56,382.74 49
PY2023 Principal investigator $148,965.97 74
PY2022 Principal investigator $217,097.35 91
PY2021 Principal investigator $222,524.42 113
PY2020 Principal investigator $248,821.20 67
PY2019 Recipient $1,250.00 1
PY2019 Principal investigator $428,314.17 79

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

91 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 MorphoSys AG $125.00 12/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398009
Principal investigator 1 MorphoSys AG $842.00 12/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398127
Principal investigator 1 MorphoSys AG $1,207.00 12/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398133
Principal investigator 1 MorphoSys AG $40.00 12/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398157
Principal investigator 1 MorphoSys AG $250.00 12/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398203
Principal investigator 1 MorphoSys AG $295.00 11/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397979
Principal investigator 1 MorphoSys AG $125.00 11/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397981
Principal investigator 1 MorphoSys AG $842.00 11/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397983
Principal investigator 1 MorphoSys AG $1,512.00 11/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397987
Principal investigator 1 MorphoSys AG $250.00 11/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397989
Principal investigator 1 MorphoSys AG $100.00 11/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398005
Principal investigator 1 MorphoSys AG $842.00 11/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398077
Principal investigator 1 MorphoSys AG $125.00 11/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398079
Principal investigator 1 MorphoSys AG $125.00 11/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398081
Principal investigator 1 MorphoSys AG $125.00 11/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398089
Principal investigator 1 MorphoSys AG $842.00 11/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398091
Principal investigator 1 MorphoSys AG $125.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397947
Principal investigator 1 MorphoSys AG $941.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397953
Principal investigator 1 MorphoSys AG $1,600.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397957
Principal investigator 1 MorphoSys AG $4,244.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397963
Principal investigator 1 MorphoSys AG $1,859.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397965
Principal investigator 1 MorphoSys AG $1,592.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397975
Principal investigator 1 MorphoSys AG $250.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398015
Principal investigator 1 MorphoSys AG $125.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398033
Principal investigator 1 MorphoSys AG $842.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398037
Principal investigator 1 MorphoSys AG $125.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398041
Principal investigator 1 MorphoSys AG $1,600.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398047
Principal investigator 1 MorphoSys AG $842.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398051
Principal investigator 1 MorphoSys AG $1,600.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398059
Principal investigator 1 MorphoSys AG $250.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398063
Principal investigator 1 MorphoSys AG $1,600.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398065
Principal investigator 1 MorphoSys AG $956.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954398067
Principal investigator 1 Novocure Inc. $850.00 10/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 950632465
Principal investigator 1 MorphoSys AG $842.00 09/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397799
Principal investigator 1 MorphoSys AG $982.00 09/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397899
Principal investigator 1 MorphoSys AG $250.00 09/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397901
Principal investigator 1 MorphoSys AG $1,532.00 09/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397907
Principal investigator 1 MorphoSys AG $1,737.00 09/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397909
Principal investigator 1 MorphoSys AG $125.00 09/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397913
Principal investigator 1 MorphoSys AG $100.00 09/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397917
Principal investigator 1 MorphoSys AG $250.00 09/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397921
Principal investigator 1 MorphoSys AG $125.00 09/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397931
Principal investigator 1 MorphoSys AG $125.00 09/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397933
Principal investigator 1 MorphoSys AG $982.00 09/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397937
Principal investigator 1 MorphoSys AG $125.00 09/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397939
Principal investigator 1 MorphoSys AG $842.00 09/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397941
Principal investigator 1 MorphoSys AG $100.00 09/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397943
Principal investigator 1 MorphoSys AG $2,587.00 08/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397779
Principal investigator 1 MorphoSys AG $200.00 08/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397781
Principal investigator 1 MorphoSys AG $130.00 08/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397783
Principal investigator 1 MorphoSys AG $100.00 08/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397785
Principal investigator 1 MorphoSys AG $250.00 08/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397789
Principal investigator 1 MorphoSys AG $500.00 08/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397797
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,028.00 07/15/2022 Non-covered Recipient Entity
Texas Oncology
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in US Community Oncology Practices No dispute reported 06/30/2026 933188237
Principal investigator 1 MorphoSys AG $200.00 07/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397761
Principal investigator 1 MorphoSys AG $1,600.00 07/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397777
Principal investigator 1 MorphoSys AG $1,600.00 07/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397813
Principal investigator 1 MorphoSys AG $956.00 07/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397815
Principal investigator 1 MorphoSys AG $956.00 07/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397817
Principal investigator 1 MorphoSys AG $1,600.00 07/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397819
Principal investigator 1 MorphoSys AG $1,600.00 07/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397835
Principal investigator 1 Novocure Inc. $850.00 07/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 950632403
Principal investigator 1 Novartis Pharmaceuticals Corporation $756.00 06/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY PA SOUTHWEST FT WORTH
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LEE011 IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WHO RECEIVED NO PRIOR HORMONAL THERAPY FOR ADVANCED DI No dispute reported 06/30/2026 909420461
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $132,850.00 05/20/2022 Non-covered Recipient Entity
Us Oncology
Phase IIA CTLA4 NF Randomized chemo combo study in mCRPC - A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 933191901
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,090.00 04/15/2022 Non-covered Recipient Entity
Texas Oncology
Phase II III 1L MSS CRC Nivo SOC vs SOC - An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer No dispute reported 06/30/2026 933191231
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $956.00 04/15/2022 Non-covered Recipient Entity
Texas Oncology
Phase III 1L Gastric nivo ipi vs nivo CT vs CT No dispute reported 06/30/2026 933193125
Principal investigator 1 Novocure Inc. $850.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 950632359
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $638.00 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL???: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 890236525
Principal investigator 1 Seagen Inc. $169.35 04/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 917887725
Principal investigator 1 Acerta Pharma LLC $6,397.00 03/23/2022 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 914596385
Principal investigator 1 Celgene Corporation $714.00 02/15/2022 Non-covered Recipient Entity
Texas Oncology
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 937185167
Principal investigator 2 Celgene Corporation $2,142.00 02/15/2022 Non-covered Recipient Entity
Texas Oncology
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 937185191
Principal investigator 1 Seagen Inc. $182.00 02/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY - BEDFORD
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 917887675
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,375.00 02/10/2022 Non-covered Recipient Entity
Us Oncology Res Llc
An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CheckMate 627) No dispute reported 06/30/2026 933187743
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,458.00 01/18/2022 Non-covered Recipient Entity
Us Oncology Res Llc
Phase II III 1L MSS CRC Nivo SOC vs SOC - An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer No dispute reported 06/30/2026 933191263
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,250.00 01/18/2022 Non-covered Recipient Entity
Us Oncology Res Llc
Phase III 1L Gastric nivo ipi vs nivo CT vs CT No dispute reported 06/30/2026 933193149
Principal investigator 1 BeiGene, Ltd. $956.00 01/15/2022 Non-covered Recipient Entity
Texas Oncology, P.A.
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies No dispute reported 06/30/2026 933753077
Principal investigator 1 Celgene Corporation $1,428.00 01/15/2022 Non-covered Recipient Entity
Texas Oncology
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 937185207
Principal investigator 1 MorphoSys AG $842.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397699
Principal investigator 1 MorphoSys AG $1,207.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397701
Principal investigator 1 MorphoSys AG $125.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397703
Principal investigator 1 MorphoSys AG $250.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397713
Principal investigator 1 MorphoSys AG $956.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397725
Principal investigator 1 MorphoSys AG $1,512.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397727
Principal investigator 1 MorphoSys AG $842.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397741
Principal investigator 1 MorphoSys AG $842.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397743
Principal investigator 1 MorphoSys AG $125.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397745
Principal investigator 1 MorphoSys AG $125.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397749
Principal investigator 1 MorphoSys AG $250.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397757
Principal investigator 1 Novocure Inc. $850.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 950632329
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $638.00 01/15/2022 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 890235945